Targeted Cell Fusion Boosts Monoclonal Antibody Production Sixfold

Monoclonal antibodies (mAbs) are among the most important tools in modern medicine—used as cancer therapies, autoimmune treatments, diagnostics, and research reagents. Yet the foundational method for producing them, hybridoma technology, has barely changed since Köhler and Milstein introduced it in 1975. A major bottleneck is the extremely low fusion efficiency (~5×10⁻⁶) when mixing whole spleen cells with immortal myeloma cells, meaning most antibody-producing B cells are simply lost in the process.

Researchers at Université Paris Saclay/CEA/INRAE set out to fix two core problems: random pairing of cell fusion partners, and low efficiency of polyethylene glycol (PEG)-based fusion. Their strategy was to isolate the rarest, most potent antibody-secreting cells (ASCs)—plasmablasts and plasma cells—from immunized mouse spleens before attempting fusion, then use electrofusion rather than PEG.

The team developed a five-marker flow cytometry panel (CD3, TACI, CD138, MHC-II, B220) to identify distinct ASC subpopulations. In immunized mice, a TACI-high/CD138-high/B220-low-to-int/MHC-II-high subset (termed P2, consistent with a plasmablast phenotype) expanded markedly compared to naïve mice and secreted approximately twice as many antigen-specific antibodies as the next best population (P3, plasma cell-like). A third population (P1), despite expressing high surface IgG, secreted no measurable antibodies and proved to be non-productive. These phenotypic distinctions were reproducible across different antigens (NheB and VIM-I) and independent mouse cohorts.

Applying this knowledge, the researchers sorted TACI-high/CD138-high ASCs and performed electrofusion with myeloma cells using a protocol adapted for small cell numbers (<10⁶ cells). The results were striking: 100% of seeded culture wells contained viable hybridomas from sorted ASCs, compared to only 40% from unsorted electrofusion and an even lower yield from conventional PEG fusion. Critically, more than 60% of hybridomas from sorted ASCs secreted antigen-specific mAbs, including IgG antibodies with dissociation constants below 10⁻⁹ M—indicating high binding affinity. In contrast, unsorted electrofusion produced a much lower proportion of antigen-specific secreting hybridomas.

This work is significant because it demonstrates that pre-screening ASCs by surface phenotype can act as a powerful enrichment step, dramatically increasing the signal-to-noise ratio in hybridoma generation. The method is practical: it relies on standard flow cytometry equipment and does not require single-cell sequencing or recombinant antibody cloning pipelines. While single-B-cell recombinant technologies offer long-term genetic stability advantages, they remain technically demanding. This optimized hybridoma approach preserves the simplicity and robustness that have kept the technology relevant for five decades, while delivering substantially better yields and antibody quality.